Literature DB >> 26373412

Consolidative Radiation in DLBCL: Evidence-Based Recommendations.

David C Hodgson1,2, N George Mikhaeel3.   

Abstract

Radiation therapy (RT) has been described as the most effective single agent in the treatment of lymphoma; however, contemporary lymphoma treatment rarely relies on single agents. In the modern era, the selection of appropriate patients for combined modality therapy has become increasingly complex over the last decade with the transition to immunochemotherapy, the emergence of functional imaging for response evaluation, and the improvement in conformal avoidance of normal tissues when delivering RT. Recent evidence demonstrates that selected patients with DLBCL have significantly better outcomes when RT is added to immunochemotherapy; however, there are important knowledge gaps regarding the use of functional imaging to facilitate treatment selection. This article will review the current evidence regarding the optimal use of combined modality therapy for DLBCL.

Entities:  

Keywords:  Combined modality treatment; Diffuse large B-cell lymphoma; Lymphoma; Positron emission topography; Radiation; Radiotherapy

Mesh:

Substances:

Year:  2015        PMID: 26373412     DOI: 10.1007/s11912-015-0472-y

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  38 in total

1.  CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  Christophe Bonnet; Georges Fillet; Nicolas Mounier; Gérard Ganem; Thierry Jo Molina; Catherine Thiéblemont; Christophe Fermé; Bruno Quesnel; Claude Martin; Christian Gisselbrecht; Hervé Tilly; Félix Reyes
Journal:  J Clin Oncol       Date:  2007-01-16       Impact factor: 44.544

Review 2.  When should FDG-PET be used in the modern management of lymphoma?

Authors:  Sally Fiona Barrington; Nabegh George Mikhaeel
Journal:  Br J Haematol       Date:  2013-10-17       Impact factor: 6.998

3.  The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans.

Authors:  J A Dorth; J P Chino; L R Prosnitz; L F Diehl; A W Beaven; R E Coleman; C R Kelsey
Journal:  Ann Oncol       Date:  2010-07-30       Impact factor: 32.976

4.  Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group.

Authors:  Tim Illidge; Lena Specht; Joachim Yahalom; Berthe Aleman; Anne Kiil Berthelsen; Louis Constine; Bouthaina Dabaja; Kavita Dharmarajan; Andrea Ng; Umberto Ricardi; Andrew Wirth
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-01       Impact factor: 7.038

5.  Risk of second cancer after treatment of aggressive non-Hodgkin's lymphoma; an EORTC cohort study.

Authors:  Elizabeth C Moser; Evert M Noordijk; Flora E van Leeuwen; Joke W Baars; José Thomas; Patrice Carde; Jacobus H Meerwaldt; Martine van Glabbeke; Hanneke C Kluin-Nelemans
Journal:  Haematologica       Date:  2006-10-17       Impact factor: 9.941

6.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.

Authors:  Bruce D Cheson; Richard I Fisher; Sally F Barrington; Franco Cavalli; Lawrence H Schwartz; Emanuele Zucca; T Andrew Lister
Journal:  J Clin Oncol       Date:  2014-09-20       Impact factor: 44.544

7.  Consolidative radiation therapy for stage III Hodgkin lymphoma in patients who achieve complete response after ABVD chemotherapy.

Authors:  Jack Phan; Ali Mazloom; Mirna Abboud; Mohammad Salehpour; Valerie Reed; Tony Zreik; Ferial Shihadeh; Christine Fisher; Christine Wogan; Bouthaina Dabaja
Journal:  Am J Clin Oncol       Date:  2011-10       Impact factor: 2.339

8.  Brief chemotherapy and involved-region irradiation for limited-stage diffuse large-cell lymphoma: an 18-year experience from the British Columbia Cancer Agency.

Authors:  Tamara N Shenkier; Nicholas Voss; Randall Fairey; Randy D Gascoyne; Paul Hoskins; Richard Klasa; Paul Klimo; Susan E O'Reilly; Simon Sutcliffe; Joseph M Connors
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

9.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.

Authors:  Michael Pfreundschuh; Anthony D Ho; Eva Cavallin-Stahl; Max Wolf; Ruth Pettengell; Ingrid Vasova; Andrew Belch; Jan Walewski; Pier-Luigi Zinzani; Walter Mingrone; Stein Kvaloy; Ofer Shpilberg; Ulrich Jaeger; Mads Hansen; Claudia Corrado; Adriana Scheliga; Markus Loeffler; Evelyn Kuhnt
Journal:  Lancet Oncol       Date:  2008-04-08       Impact factor: 41.316

10.  Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.

Authors:  Sandra J Horning; Edie Weller; KyungMann Kim; John D Earle; Michael J O'Connell; Thomas M Habermann; John H Glick
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

View more
  1 in total

Review 1.  The Management of Lymphoma in the Setting of Pregnancy.

Authors:  Chelsea C Pinnix; Therese Y Andraos; Sarah Milgrom; Michelle A Fanale
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.